Pomegranate Extract for Health & Longevity - Quick Reference Sheet

Pomegranate Extract for Health & Longevity

Created on 08/21/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

A daily capsule of concentrated pomegranate compounds. Its most reliable effects are a modest fall in blood pressure and lower markers of inflammation, largest in those starting with raised readings. Cholesterol changes are small and inconsistent. Safety is reassuring; loose stools at high doses are the main problem. About one in ten cannot access the cell-renewal effects. (Full Review)

Protocol

Standard dose
500–1,000 mg daily
Fruit or peel extract, taken continuously. Best benefit-to-tolerance ratio.
Standardization target
30–40% punicalagins
Matches trial material more closely than ellagic acid standardization.
Metabotype testing
Urinary urolithin profiling
Identifies non-producers, for whom the purified metabolite is the only route; a higher extract dose does not substitute.
Time to effect
Blood pressure
2–4 weeks
Systolic and diastolic pressure
Inflammatory markers
6–12 weeks
C-reactive protein, interleukin-6
Acute blood flow
30 minutes
Single 1,000 mg dose 30 minutes before exertion

Benefits

Contraindications
  • Documented pomegranate or lipid transfer protein allergy (including severe stone-fruit allergy with prior anaphylaxis)
  • Pregnant and breastfeeding women
  • Solid organ transplant recipients on calcineurin inhibitors (unless drug levels are actively monitored)
  • Symptomatic hypotension (systolic pressure below 100 mmHg with orthostatic symptoms)
  • Within two weeks of major surgery
Key Interactions
  • Antihypertensives (amlodipine, lisinopril, losartan, hydrochlorothiazide)
  • Warfarin
  • CYP3A4 substrates with narrow margins (tacrolimus, ciclosporin, sirolimus)
  • CYP2C9 substrates (phenytoin, glipizide, celecoxib)
  • Statins (rosuvastatin, simvastatin, atorvastatin)
  • Over-the-counter agents (ibuprofen, naproxen, aspirin)
  • Pressure-lowering supplements (beetroot nitrate, garlic extract, omega-3 fatty acids, magnesium, hibiscus)
  • Iron supplements and iron-rich meals
  • Purified urolithin A supplements
  • Other interventions (timed fasting, low-fiber diets)

Risk & Side Effects

  • High: Gastrointestinal upset and diarrhea
  • Medium: Additive blood pressure lowering; altered drug metabolism
  • Low: Allergic reactions including anaphylaxis; reduced non-heme iron absorption; flu-like and urinary symptoms
  • Speculative: Statin-associated muscle injury; hormonal activity in hormone-sensitive conditions; alkaloid exposure from root or bark material

Monitoring

Marker Target Why
Home systolic blood pressure 110–120 mmHg Primary and best-evidenced endpoint
Home diastolic blood pressure 65–80 mmHg Detects additive hypotension when stacked with medication
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks the inflammation signal with the strongest pooled evidence
Interleukin-6 Below 1.5 pg/mL More sensitive than C-reactive protein; moved reliably in the 55–70 age trial
Apolipoprotein B Below 80 mg/dL Confirms whether lipid expectations are being met, which pooled data suggest they will not be
Oxidized low-density lipoprotein Below 60 U/L Mechanistically the marker pomegranate moves most consistently
Fasting glucose 75–86 mg/dL Detects the small glycemic effect and rules out drift
Glycated hemoglobin Below 5.4% Three-month glucose average, insensitive to single-day variation
Ferritin 50–150 ng/mL (women), 50–200 ng/mL (men) Catches the tannin-mediated iron absorption risk
Alanine aminotransferase Below 25 U/L (men), below 20 U/L (women) Confirms no liver signal; pooled data suggest improvement rather than harm
Prostate-specific antigen No established target; change from personal baseline and doubling time Relevant only to men with a prostate cancer history
Urinary urolithin profile No established range; producer or non-producer status Determines whether the metabolite-dependent benefits are accessible at all

Cadence: Weekly blood pressure for four weeks, then monthly; fasting panel repeated at 12 weeks, then every 6–12 months; ferritin annually for menstruating women, endurance athletes, and vegetarians.

Qualitative Assessment

  • Perceived recovery in the 24–48 hours after hard training sessions
  • Exercise tolerance and breathlessness at a fixed submaximal effort
  • Lightheadedness on standing, which flags additive blood pressure lowering
  • Digestive comfort and stool consistency, the earliest sign of an excessive dose
  • Subjective energy and mental clarity through the afternoon